If you’re a federal employee and have questions about continuing coverage, please speak to your Patient Benefits Specialist and visit our insurance page here: virginiacancerspecialists.com/insurance/Exciting News! Our Gainesville Office has moved to Bristow9450 Innovation Drive, Manassas, VA 20110.  Same great providers and care team, same exceptional care, new, larger space to better serve our patients.

anti-NY-ESO1 TCR-transduced autologous CD62L+-derived T lymphocytes

Human autologous CD62L-positive T lymphocytes transduced with a retroviral vector encoding a T cell receptor (TCR) specific for the cancer-testis antigen NY-ESO-1, with potential antineoplastic activity. Following leukapheresis, isolation of lymphocytes, expansion ex vivo, transduction, and reintroduction into the patient, the anti-NY-ESO1 TCR-transduced autologous CD62L+-derived T lymphocytes bind to NY-ESO-1-overexpressing tumor cells. This may result in cytotoxic T-lymphocyte (CTL)-mediated elimination of NY-ESO-1-positive cancer cells. NY-ESO-1, a tumor associated antigen (TAA), is found in normal testis and on the surface of various tumor cell types. CD62L, also called L-selectin, is a lymphoid homing receptor and differentiation marker and is expressed on a subset of CD8-positive T-lymphocytes; it is involved in the migration of T-lymphocytes to lymph nodes and may improve the efficacy for ex vivo-expanded T-cells following adoptive cell therapy. Check for active clinical trials using this agent. (NCI Thesaurus)

Related Posts

Award Winning Physicians

Our Physicians work for you, ensuring the highest standard of care.

Learn More